Implementation Science Open Access Study Protocol the Preventing Recurrent Vascular Events and Neurological Worsening through Intensive Organized Case-management (prevention) Trial Protocol [clinicaltrials.gov Identifier: Nct00931788]
暂无分享,去创建一个
F. McAlister | S. Majumdar | R. Tsuyuki | R. Padwal | A. Shuaib | N. Dean | S. Grover | Miriam Fradette | Ann E. Thompson
[1] Tom Fahey,et al. Interventions used to improve control of blood pressure in patients with hypertension. , 2010, The Cochrane database of systematic reviews.
[2] J. Grimshaw,et al. The Enhancing Secondary Prevention in Coronary Artery Disease trial , 2009, Canadian Medical Association Journal.
[3] G. Elwyn,et al. Involving patients in cardiovascular risk management with nurse-led clinics: a cluster randomized controlled trial , 2009, Canadian Medical Association Journal.
[4] Robert Dufour,et al. Canadian Cardiovascular Society / Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations , 2009 .
[5] S. Yusuf,et al. Telmisartan to prevent recurrent stroke and cardiovascular events. , 2008, The New England journal of medicine.
[6] Mark Bayley,et al. Toward a more effective approach to stroke: Canadian Best Practice Recommendations for Stroke Care , 2008, Canadian Medical Association Journal.
[7] F. McAlister,et al. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials , 2008, Canadian Medical Association Journal.
[8] R. Collins,et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths , 2007, The Lancet.
[9] Lawrence Joseph,et al. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial. , 2007, Archives of internal medicine.
[10] S. Gutnikov,et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison , 2007, The Lancet.
[11] M. Al-mallah,et al. Active Lipid Management In Coronary Artery Disease (ALMICAD) study. , 2007, The American journal of medicine.
[12] Ashley C. Mull. Validation and Refinement of Scores to Predict Very Early Stroke Risk after Transient Ischemic Attack , 2007 .
[13] J. Spence,et al. Combining Multiple Approaches for the Secondary Prevention of Vascular Events After Stroke: A Quantitative Modeling Study , 2007, Stroke.
[14] Lawrence A Leiter,et al. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. , 2007, The Canadian journal of cardiology.
[15] B. Rowe,et al. Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial , 2007, Osteoporosis International.
[16] Jeannie K. Lee,et al. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. , 2006, JAMA.
[17] K. Shojania,et al. Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis. , 2006, JAMA.
[18] M. Woodward,et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial , 2006, Journal of hypertension.
[19] J. Szalai,et al. Effect of nurse-directed hypertension treatment among First Nations people with existing hypertension and diabetes mellitus: the Diabetes Risk Evaluation and Microalbuminuria (DREAM 3) randomized controlled trial , 2006, Canadian Medical Association Journal.
[20] B. Vandermeer,et al. Randomized Trials of Secondary Prevention Programs in Coronary Artery Disease: A Systematic Review , 2005 .
[21] J. Sutherland,et al. Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME study) , 2005, Journal of General Internal Medicine.
[22] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[23] B. Psaty,et al. Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly , 2005, Neurology.
[24] A. Senthilselvan,et al. The Impact of a Stroke Prevention Clinic in Diagnosing Modifiable Risk Factors for Stroke , 2005, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[25] F. McAlister,et al. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis , 2004, Canadian Medical Association Journal.
[26] S. Yusuf,et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.
[27] J. Tu,et al. The high risk of stroke immediately after transient ischemic attack , 2004, Neurology.
[28] S. Majumdar,et al. Controlled trial of a multifaceted intervention for improving quality of care for rural patients with type 2 diabetes. , 2003, Diabetes care.
[29] J. Leonardi-Bee,et al. Blood Pressure Reduction and Secondary Prevention of Stroke and Other Vascular Events: A Systematic Review , 2003, Stroke.
[30] J. Spinelli,et al. The Extensive Lifestyle Management Intervention (ELMI) following cardiac rehabilitation trial. , 2003, European heart journal.
[31] L. Till,et al. Assessment of Clinical Pharmacist Management of Lipid-Lowering Therapy in a Primary Care Setting , 2003, Journal of managed care pharmacy : JMCP.
[32] S. Lewington. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002) , 2003 .
[33] Majid Ezzati,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[34] S. Straus,et al. New evidence for stroke prevention: scientific review. , 2002, JAMA.
[35] S. Majumdar,et al. How Well Are Hypertension, Hyperlipidemia, Diabetes, and Smoking Managed After a Stroke or Transient Ischemic Attack? , 2002, Stroke.
[36] K. Teo,et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). , 2002, Archives of internal medicine.
[37] D. Johnston. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack , 2001, The Lancet.
[38] D. Malone,et al. Clinical and Economic Impact of Ambulatory Care Clinical Pharmacists in Management of Dyslipidemia in Older Adults: The IMPROVE Study , 2000 .
[39] C. Rubino,et al. Effect of a Clinical Pharmacist‐Managed Lipid Clinic on Achieving National Cholesterol Education Program Low‐Density Lipoprotein Goals , 2000, Pharmacotherapy.
[40] L. Bero,et al. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. , 2000, The Cochrane database of systematic reviews.
[41] S. Pocock,et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. , 1997, Stroke.
[42] M. Joffres,et al. Awareness, treatment, and control of hypertension in Canada. , 1997, American journal of hypertension.
[43] E. Pfeiffer. A Short Portable Mental Status Questionnaire for the Assessment of Organic Brain Deficit in Elderly Patients † , 1975, Journal of the American Geriatrics Society.
[44] L. Coupal,et al. Discussing Coronary Risk with Patients to Improve Blood Pressure Treatment: Secondary Results from the CHECK-UP Study , 2008, Journal of General Internal Medicine.
[45] S. Sutherland,et al. The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. , 2008, Journal of the American Pharmacists Association : JAPhA.
[46] Ross T Tsuyuki,et al. Impact of opinion leader-endorsed evidence summaries on the quality of prescribing for patients with cardiovascular disease: a randomized controlled trial. , 2007, American heart journal.
[47] T. Einarson,et al. Hypertenion: Sensitivity of Patient Outcomes to Pharmacist Interventions. Part II: Systematic Review and Meta-Analysis in Hypertension Management , 2007, The Annals of pharmacotherapy.
[48] J. Farmer. High-dose atorvastatin after stroke or transient ischemic attack. , 2007, Current atherosclerosis reports.
[49] V. Babikian,et al. Risk factor modification in stroke prevention: the experience of a stroke clinic. , 1999, Stroke.
[50] R. Bloch,et al. Interobserver agreement for the assessment of handicap in stroke patients. , 1988, Stroke.